Test Price
2,800 AED✅ Home Collection Available
COG1 Gene Glycosylation Disorder Type 2g (CDG-2g) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Regulatory Compliance: DHA-licensed laboratory (Facility License 1143) adhering to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning Health Information and Communication Technology.
Clinical Governance: All procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Test Overview & Methodology
The COG1 gene NGS test analyzes the entire coding region for pathogenic variants causing congenital disorder of glycosylation type IIg, a neurometabolic condition. Next-Generation Sequencing (NGS) with LC-MS/MS validation ensures >99.9% coverage of all single nucleotide variants, indels, and copy number variants.
| Feature | Our Test (COG1 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% coverage, detects all SNVs, indels, and CNVs | ~99% for targeted exons only; may miss deep intronic or CNVs |
| Methodology | Next‑Generation Sequencing (NGS) with LC‑MS/MS validation | Sanger dideoxy sequencing per exon |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks (if multiple exons) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I understand families’ concerns when a child presents with developmental delays and seizures. This test, when interpreted with clinical findings, can confirm a rare glycosylation disorder and guide targeted support. Always correlate results with a detailed metabolic work‑up.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Precautions
Before proceeding with genetic testing, consider the following clinical guidelines:
- Exclusion: Patients with acute intercurrent illness (e.g., fever >38.5°C) should postpone non‑urgent genetic testing.
- Exclusion: Recent blood transfusion (<4 weeks) may cause DNA admixture; reschedule.
- ER Red Flag: New‑onset severe neurological deterioration (status epilepticus, loss of consciousness) requires emergency care immediately.
- ER Red Flag: Signs of metabolic crisis (vomiting, lethargy, hypoglycemia) require urgent pediatric evaluation.
Important Medication & Consent Advisory
Do not discontinue prescribed medication without consulting your physician. All tests require written informed consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the COG1 NGS test and who needs it?
The COG1 NGS test detects pathogenic DNA variants in the COG1 gene to diagnose congenital disorder of glycosylation type IIg, indicated for unexplained developmental delay, hypotonia, seizures, and dysmorphic features.
2. How accurate is this and what does a negative result mean?
With >99.9% analytic sensitivity, a negative COG1 NGS result rules out pathogenic variants in the gene but may not exclude other glycosylation disorders or novel variants outside the coding region. Additional biochemical testing may be recommended.
3. How is the sample collected and is home collection available in UAE?
Sample collection is performed via a simple blood draw or dry blood spot card. Our DHA‑licensed mobile phlebotomy team provides hospital‑grade home collection across all Emirates from 8 AM to 11 PM daily. For standard peripheral whole blood specimens, home phlebotomy is fully enabled.
4. What is the turnaround time and how will I receive results?
Turnaround time is 3–4 weeks from sample receipt. Results are delivered via secure electronic report and may be discussed in a telephonic post-test consultation with a genetic counselor upon request.
UAE Regulatory & Data Privacy Adherence
Your data is protected under the highest standards.
All clinical data handled by DNA Labs UAE complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our DHA-licensed facility (License 1143) ensures full adherence to UAE health information confidentiality and security requirements.
Clinical & Logistical Metadata
| Test Name | COG1 Gene Glycosylation Disorder Type 2g (CDG-2g) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or Dry Blood Spot (DBS) – VIP Mobile Phlebotomy & Cold-Chain Home Collection available |
| Methodology Used | Next-Generation Sequencing (NGS) with LC-MS/MS validation |
| ICD-10-CM Code | E77.8 (Other disorders of glycoprotein metabolism) |
| LOINC Code | 81247-4 (Hereditary disease sequencing) |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians